Phase II trial of S-1 based therapy+/-Trastuzmab combination therapy for unresectable gastric cancer

Phase II trial of S-1 based therapy+/-Trastuzmab combination therapy for unresectable gastric cancer - S-1 based therapy+/-Trastuzmab combination therapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006058

Enrollment

Registered

2011-07-28

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable gastric cancer

Interventions

S-1 80mg/m2 day1-14 CDDP 60mg/m2 day1 Trastuzumab 6mg/kg day1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All of people were eligible for inclusion if they had histologically comformed inoperable, recurrent, or metastatic adenocarcinoma. ECOG performance status 0-2: adequate organ function; and measurable disease

Exclusion criteria

Exclusion criteria: We exclude all patient who are not eligible for the inclusion

Design outcomes

Primary

Measure	Time frame
response rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026